Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4512593 | 0.96 | ACHE (1.00) | ACHEBCHE | |
| SCHEMBL2402320 | 0.95 | ACHE (0.90) | ACHEBCHE | |
| Icopezil SCHEMBL2231222 | 0.94 | ACHE (1.00) | ACHEBCHE | |
| Icopezil SCHEMBL3339253 | 0.94 | ACHE (1.00) | ACHEBCHE | |
| SCHEMBL220485 | 0.92 | ACHE (1.00) | ACHEBCHE | |
| SCHEMBL2405514 | 0.91 | ACHE (0.84) | ACHEBCHE | |
| Icopezil SCHEMBL9276199 | 0.91 | ACHE (0.93) | ACHEBCHE | |
| Icopezil SCHEMBL9276204 | 0.91 | ACHE (0.93) | ACHEBCHE | |
| SCHEMBL2403486 | 0.91 | ACHE (0.82) | ACHEBCHE | |
| SCHEMBL6198882 | 0.84 | ACHE (0.73) | ACHEBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 776 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4635489-A1 | COMPOSITION FOR PREVENTING OR TREATING SIDE EFFECTS OF CHOLINESTERASE INHIBITORS | Dr.Noah Biotech Inc. (KR) | 2025-10-22 | — | — | EP | claimed |
| EP-4509120-A2 | COMPOSITIONS FOR IMPROVING CELL VIABILITY AND METHODS OF USE THEREOF | Amylyx Pharmaceuticals Inc. (US) | 2025-02-19 | — | — | EP | claimed |
| US-12186330-B2 | Compositions for improving cell viability and methods of use thereof | Amylyx Pharmaceuticals Inc. (US) | 2025-01-07 | — | — | US | claimed |
| US-20240423965-A1 | FIXED DOSE COMBINATION OF CHOLINESTERASE INHIBITOR AND A QUATERNARY AMMONIUM ANTIMUSCARINIC AGENT TO TREAT NEURODEGENERATIVE COGNITIVE DISORDERS | QAAM PHARMACEUTICALS LLC (US) | 2024-12-26 | — | — | US | claimed |
| EP-4473964-A1 | COMPOSITION COMPRISING BETA BLOCKER AND CHOLINESTERASE INHIBITOR FOR TREATMENT OF NEURODEGENERATIVE DISEASE | Dr.Noah Biotech Inc. (KR) | 2024-12-11 | — | — | EP | claimed |
| CN-118647376-A | Compositions comprising a beta blocker and a cholinesterase inhibitor for the treatment of neurodegenerative diseases | 诺亚博士生物科技有限公司 | 2024-09-13 | — | — | CN | claimed |
| WO-2024128473-A1 | COMPOSITION FOR PREVENTING OR TREATING SIDE EFFECTS OF CHOLINESTERASE INHIBITORS | 닥터노아바이오텍 주식회사 | 2024-06-20 | — | — | WO | claimed |
| US-20240148711-A1 | COMPOSITION COMPRISING BETA BLOCKER AND CHOLINESTERASE INHIBITOR FOR TREATMENT OF NEURODEGENERATIVE DISEASE | DR.NOAH BIOTECH INC. (KR) | 2024-05-09 | — | — | US | claimed |
| US-20240066017-A1 | PREVENTION OR TREATMENT OF BRAIN DISEASE AND ADVERSE EFFECTS OF CHOLINESTERASE INHIBITORS | DR. NOAH BIOTECH INC. (KR) | 2024-02-29 | — | — | US | claimed |
| US-20230414575-A1 | MK2 ACTIVATING COMPOUNDS FOR USE IN TREATING VASCULAR LEAK AND ENDOTHELIAL BARRIER DISORDERS | AKTTYVA THERAPEUTICS INC (US) | 2023-12-28 | — | — | US | claimed |
| US-20020028834-A1 | Heterocyclic-cyclic amine derivatives | VILLALOBOS ANABELLA (US) | 2002-03-07 | — | — | US | claimed |
| US-20020016334-A1 | Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD) | COE JOTHAM WADSWORTH (US) | 2002-02-07 | — | — | US | claimed |
| EP-1177798-A2 | A pharmaceutical composition for the treatment of attention deficit hyperactivity disorder(ADHD) comprising a nicotine receptor partial agonist and anti-ADHD agent | Pfizer Products Inc. (US) | 2002-02-06 | — | — | EP | claimed |
| WO-2001085145-A2 | A PHARMACEUTICAL COMPOSITION AND METHOD OF TREATMENT OF DISEASES OF COGNITIVE DYSFUNCTION IN A MAMMAL | PFIZER PRODUCTS INC. (US) | 2001-11-15 | — | — | WO | claimed |
| US-20010036949-A1 | Pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal | PFIZER PRODUCTS INC. | 2001-11-01 | — | — | US | claimed |
| CN-1285742-A | Combination of active principles for treating senile dementia such as alzheimer dementia | SANOFI SYNTHELABO (FR) | 2001-02-28 | — | — | CN | claimed |
| EP-0976404-A2 | A pharmaceutical composition for the prevention and treatment of diseases of cognitive dysfunction in a mammal | Pfizer Products Inc. (US) | 2000-02-02 | — | — | EP | claimed |
| JP-2659107-B2 | — | EISAI CO LTD (JP) | 1997-09-30 | — | — | JP | claimed |
| EP-0646115-A1 | HETEROCYCLIC-CYCLIC AMINE DERIVATIVES | Eisai Co., Ltd. (JP) | 1995-04-05 | — | — | EP | claimed |
| WO-1992017475-A1 | HETEROCYCLIC-CYCLIC AMINE DERIVATIVES | PFIZER INC. (US) | 1992-10-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240148711-A1 | COMPOSITION COMPRISING BETA BLOCKER AND CHOLINESTERASE INHIBITOR FOR TREATMENT OF NEURODEGENERATIVE DISEASE | ACHE, BACE1, CHRNB4 | ACHE 1/4885BCHE 6/4885 |
| US-20020016334-A1 | Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD) | CHRNB4, CHRNA10, CHRNA7 | ACHE 59/4885BCHE 211/4885 |
| US-20240066017-A1 | PREVENTION OR TREATMENT OF BRAIN DISEASE AND ADVERSE EFFECTS OF CHOLINESTERASE INHIBITORS | ACHE, BCHE, CHAT | ACHE 1/4885BCHE 2/4885 |
| US-20240423965-A1 | FIXED DOSE COMBINATION OF CHOLINESTERASE INHIBITOR AND A QUATERNARY AMMONIUM ANTIMUSCARINIC AGENT TO TREAT NEURODEGENERATIVE COGNITIVE DISORDERS | ACHE, BCHE, CHRM1 | ACHE 1/4885BCHE 2/4885 |
| US-20020028834-A1 | Heterocyclic-cyclic amine derivatives | BCHE, ACHE, CHRM1 | ACHE 2/4885BCHE 1/4885 |
| US-12186330-B2 | Compositions for improving cell viability and methods of use thereof | HSPA9, CYP27A1, TUFM | ACHE 3040/4885BCHE 531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.